BMC Nephrology is affiliated with the UK Kidney Association
Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial
The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients.